Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Enlivex Therapeutics Ltd.

Start price
Target price
Perf. (%)
€1.51
13.04.24
€2.00
13.04.25
-0.66%
27.04.24

negative Cash Flow expected
Few uniques
Growths slower than the competition
Below average Marketposition
buy
Enlivex Therapeutics Ltd.

Start price
Target price
Perf. (%)
€1.72
11.04.24
-
11.04.25
-12.21%
14.04.24

Could be worthwhile Investment >10% per year
buy
Deutsche Pfandbriefbank AG

Start price
Target price
Perf. (%)
€5.06
09.04.24
€5.00
09.04.25
13.24%
18.05.24

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
buy
Plug Power Inc.

Start price
Target price
Perf. (%)
€2.91
08.04.24
€3.00
08.04.25
-21.66%
27.04.24

Good rating
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
buy
Cytokinetics Inc.

Start price
Target price
Perf. (%)
€66.50
07.04.24
-
07.04.25
0.75%
14.04.24

Could be very worthwhile Investment >20% year
Insmed Inc.

Start price
Target price
Perf. (%)
€25.40
07.04.24
€15.00
30.09.25
-7.09%
13.05.24

Could be very worthwhile Investment >20% year
buy
AT&S Austria Technologie & Systemtechnik AG

Start price
Target price
Perf. (%)
€19.31
04.04.24
€26.00
04.04.25
-1.61%
13.04.24

buy
Cal-Maine Foods Inc.

Start price
Target price
Perf. (%)
€55.84
04.04.24
-
04.04.25
2.94%
13.04.24

Hypoport SE

Start price
Target price
Perf. (%)
€235.20
02.04.24
€166.00
02.04.25
-4.76%
13.04.24

Probably not worthwhile Investment
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
buy
Deutsche Pfandbriefbank AG

Start price
Target price
Perf. (%)
€4.81
27.03.24
€5.00
27.03.25
5.24%
09.04.24

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Akebia Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.88
26.03.24
-
26.03.25
-18.09%
31.03.24

Risky Investment
buy
Hypoport SE

Start price
Target price
Perf. (%)
€239.60
22.03.24
-
22.03.25
13.11%
06.05.24

Very low/no dividend yield expected
EBIT decline/stagnation expected
buy
SMA Solar Technology AG

Start price
Target price
Perf. (%)
€55.00
22.03.24
-
22.04.24
-13.27%
23.04.24

Could be worthwhile Investment >10% per year
buy
Marathon Digital Holdings

Start price
Target price
Perf. (%)
€16.94
19.03.24
€22.00
19.03.25
14.24%
30.03.24

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Some uniques
Risky balance sheet
buy
Super Micro Computer

Start price
Target price
Perf. (%)
€828.60
19.03.24
€900.00
19.03.25
18.14%
30.03.24

Could be very worthwhile Investment >20% year
Higher EBIT margin than peer group
Capable Management
Low dividend yield expected
Super Micro Computer

Start price
Target price
Perf. (%)
€973.00
18.03.24
€666.00
18.03.25
0.61%
30.03.24

Probably not worthwhile Investment
High valuation
Low dividend yield expected
negative Cash Flow expected
buy
ABC Arbitrage S.A.

Start price
Target price
Perf. (%)
€3.85
18.03.24
-
18.03.25
2.47%
30.03.24

Could be worthwhile Investment >10% per year
buy
Akebia Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.51
18.03.24
-
18.03.25
2.26%
30.03.24

Could be worthwhile Investment >10% per year
Akebia Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.51
17.03.24
€0.30
30.11.25
76.96%
28.03.24

Could be very worthwhile Investment >20% year
buy
Inventiva SA

Start price
Target price
Perf. (%)
€3.71
17.03.24
€5.00
31.01.26
-2.70%
19.03.24

Could be very worthwhile Investment >20% year
buy
Verastem Inc.

Start price
Target price
Perf. (%)
€10.20
17.03.24
€16.00
30.06.26
-8.82%
19.03.24

Could be very worthwhile Investment >20% year
buy
PNE AG

Start price
Target price
Perf. (%)
€13.94
16.03.24
€20.00
16.04.24
-5.02%
17.04.24

Could be worthwhile Investment >10% per year
buy
Akebia Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.51
16.03.24
€2.00
16.03.25
2.26%
30.03.24

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Low dividend yield expected
buy
Chromadex Corp

Start price
Target price
Perf. (%)
€2.22
16.03.24
€4.00
16.03.25
53.15%
30.03.24

EBIT decline/stagnation expected
Revenue decline/stagnation expected
High valuation
Low dividend yield expected
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€4.89
16.03.24
€48.00
16.03.25
-12.06%
30.03.24

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Rising EBIT margin expected
Low dividend yield expected